Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab
Cancer Diagnosis & Prognosis · 01.05.2026 · 6 (3) · 559-569
DOI: 10.21873/cdp.10556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.05.2026. Verfasst von Akifumi Kuwano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: Evidence supporting atezolizumab plus bevacizumab (Atez/Bev) for unresectable hepatocellular carcinoma (uHCC) in patients with Child–Pugh B (CP-B) liver function is limited. We investigated whether the prognostic significance of radiologic response differs according to hepatic reserve and evaluated the impact of baseline neutrophil-to-lymphocyte ratio (NLR). Patients and Methods: We retrospectively analyzed 105 consecutive patients with uHCC treated with Atez/Bev (CP-A, n=82; CP-B, n=23). Tumor response was assessed by modified RECIST, and overall survival (OS) was estimated using Kaplan–Meier methods. Baseline NLR was evaluated using a prespecified cut-off of 2.56. Results: Response was not evaluable more often in CP-B than in CP-A (21.7% vs. 4.8%). In CP-A, objective response and disease control were each associated with longer OS (p=0.002 and p=0.003, respectively). In CP-B, neither objective response nor disease control was significantly associated with OS; OS was similar for stable disease and objective response (10.6 vs. 10.7 months). Across the cohort, NLR
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.
- Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
Zitieren
APA
Kuwano, A., Yada, M., Tanaka, K., Hamamoto, T., Kurosaka, K., Suzuki, H., & Motomura, K. (2026). Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab. Cancer Diagnosis & Prognosis, 6(3), 559-569. https://doi.org/10.21873/cdp.10556
Vancouver
Kuwano A, Yada M, Tanaka K, Hamamoto T, Kurosaka K, Suzuki H, et al. Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab. Cancer Diagnosis & Prognosis. 2026;6(3):559-569. doi:10.21873/cdp.10556
BibTeX
@article{Kuwano2026,
author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamamoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Motomura, Kenta},
title = {Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab},
journal = {Cancer Diagnosis & Prognosis},
year = {2026},
volume = {6},
number = {3},
pages = {559--569},
doi = {10.21873/cdp.10556}
}
EUVIMED